Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

HDAC Inhibitors: Innovative Strategies for Their Design and Applications
Mateusz Daśko, Beatriz de Pascual‐Teresa, Irene Ortín, et al.
Molecules (2022) Vol. 27, Iss. 3, pp. 715-715
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives
Jingjing Pu, Ting Liu, Xuzhen Wang, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 11
A review of progress in o-aminobenzamide-based HDAC inhibitors with dual targeting capabilities for cancer therapy
Weixin Zhang, Jiao Huang, Xin-Yi Tian, et al.
European Journal of Medicinal Chemistry (2023) Vol. 259, pp. 115673-115673
Closed Access | Times Cited: 22
Potential of Synthetic and Natural Compounds as Novel Histone Deacetylase Inhibitors for the Treatment of Hematological Malignancies
Dilipkumar Pal, Khushboo Raj, Shyam Sundar Nandi, et al.
Cancers (2023) Vol. 15, Iss. 10, pp. 2808-2808
Open Access | Times Cited: 19
Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?
Sk. Abdul Amin, Samima Khatun, Shovanlal Gayen, et al.
European Journal of Medicinal Chemistry (2023) Vol. 258, pp. 115594-115594
Closed Access | Times Cited: 19
Combination of epidrugs with immune checkpoint inhibitors in cancer immunotherapy: From theory to therapy
Ruoyu Guo, Jixia Li, Jinxia Hu, et al.
International Immunopharmacology (2023) Vol. 120, pp. 110417-110417
Open Access | Times Cited: 16
The Epigenetics of Migraine
Farzin Zobdeh, Иван Иванович Еременко, Mikail A. Akan, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9127-9127
Open Access | Times Cited: 14
Navigating the GSK-3β inhibitors as versatile multi-target drug ligands in Alzheimer’s disease intervention – A comprehensive review
Nachiket Jitendra Joshi, Rajasekhar Reddy Alavala
Results in Chemistry (2024) Vol. 7, pp. 101500-101500
Open Access | Times Cited: 5
Electrochemical Synthesis of New Isoxazoles and Triazoles Tethered with Thiouracil Base as Inhibitors of Histone Deacetylases in Human Breast Cancer Cells
Divakar Vishwanath, Xi Zhang, Akshay Ravish, et al.
Molecules (2023) Vol. 28, Iss. 13, pp. 5254-5254
Open Access | Times Cited: 12
Repurposing Linezolid in Conjunction with Histone Deacetylase Inhibitor Access in the Realm of Glioblastoma Therapies
I‐Chung Chen, Hong-Yi Lin, Zhengyang Liu, et al.
Journal of Medicinal Chemistry (2025)
Open Access
Anticancer efficacy of Spiruchostatin A: current insights into histone deacetylase inhibition and oncologic applications
S.M. Ibrahim, Muhammad Umer Khan, Iqra Khurram, et al.
European journal of medical research (2025) Vol. 30, Iss. 1
Open Access
Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects
Jinxiao Ru, Yuxi Wang, Zijia Li, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115800-115800
Closed Access | Times Cited: 10
Suberoylanilide Hydroxamic Acid Analogs with Heteroaryl Amide Group and Different Chain Length: Synthesis and Effect on Histone Deacetylase
Gabriele Micheletti, Carla Boga, Giacomo Drius, et al.
Molecules (2024) Vol. 29, Iss. 1, pp. 238-238
Open Access | Times Cited: 3
Metalloenzyme Inhibitors against Zoonotic Infections: Focus on Leishmania and Schistosoma
Sara Rossi, Valeria Tudino, Gabriele Carullo, et al.
ACS Infectious Diseases (2024) Vol. 10, Iss. 5, pp. 1520-1535
Closed Access | Times Cited: 3
Histone Deacetylase Inhibitors Show a Potential Leishmanicidal Effect against Leishmania braziliensis in a Mouse Infection Model and Lead to Less Toxicity than Glucantime
Luciana Ângelo de Souza, Leandro Oliveira de Andrade, Joice de Melo Agripino, et al.
ACS Omega (2025)
Open Access
Design, Synthesis, and Biological Evaluation of Novel Quinazolin-4(3H)-one-Based Histone Deacetylase 6 (HDAC6) Inhibitors for Anticancer Activity
Yogesh Mahadu Khetmalis, Ashna Fathima, Markus Schweipert, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 11044-11044
Open Access | Times Cited: 9
Novel hydroxamic acid derivative induces apoptosis and constrains autophagy in leukemic cells
Marten A. Fischer, Al‐Hassan M. Mustafa, Kristin Hausmann, et al.
Journal of Advanced Research (2023) Vol. 60, pp. 201-214
Open Access | Times Cited: 9
Hydroxamic acid hybrids: Histone deacetylase inhibitors with anticancer therapeutic potency
Yuan Jiang Pan, Haodong Hou, Bo Zhou, et al.
European Journal of Medicinal Chemistry (2023) Vol. 262, pp. 115879-115879
Closed Access | Times Cited: 8
Histone deacetylase‐mediated silencing of PSTPIP2 expression contributes to aristolochic acid nephropathy‐induced PANoptosis
Chuanting Xu, Qi Wang, Changlin Du, et al.
British Journal of Pharmacology (2023) Vol. 181, Iss. 9, pp. 1452-1473
Closed Access | Times Cited: 8
Specific epigenetic regulators serve as potential therapeutic targets in idiopathic pulmonary fibrosis
Manas Sehgal, Sharayu Manish Jakhete, Amruta Ganesh Manekar, et al.
Heliyon (2022) Vol. 8, Iss. 8, pp. e09773-e09773
Open Access | Times Cited: 14
In the quest for histone deacetylase inhibitors: current trends in the application of multilayered computational methods
Abdullahi İbrahim Uba, Gökhan Zengin
Amino Acids (2023) Vol. 55, Iss. 12, pp. 1709-1726
Closed Access | Times Cited: 7
Inhibition of acetylation, is it enough to fight cancer?
Laura López-Bañuelos, Libia Vega
Critical Reviews in Oncology/Hematology (2022) Vol. 176, pp. 103752-103752
Closed Access | Times Cited: 12
Therapeutic potential of targeting Nrf2 by panobinostat in pituitary neuroendocrine tumors
Yijun Cheng, Yuting Dai, Hao Tang, et al.
Acta Neuropathologica Communications (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 2
Histone Deacetylase Inhibitors as Cognitive Enhancers and Modifiers of Mood and Behavior
Dilipkumar Pal, Pooja Sahu, Abhishek Kumar Mishra, et al.
Current Drug Targets (2022) Vol. 24, Iss. 9, pp. 728-750
Closed Access | Times Cited: 11
The Impact of Fluorination on the Design of Histone Deacetylase Inhibitors
Duong Tien Anh, Nguyen‐Hai Nam, Brigitte Kircher, et al.
Molecules (2023) Vol. 28, Iss. 4, pp. 1973-1973
Open Access | Times Cited: 6
Alveolar ridge preservation in rat tooth extraction model by chitosan-derived epigenetic modulation scaffold
Teerawat Sukpaita, Suwabun Chirachanchai, Theerapat Chanamuangkon, et al.
Journal of Prosthodontic Research (2023) Vol. 68, Iss. 2, pp. 299-309
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top